PubMed:16920333 / 155-474 JSONTXT

{"project":"LitCoin-sentences","denotations":[{"id":"T2","span":{"begin":0,"end":319},"obj":"Sentence"}],"text":"Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine (CBZ) and oxcarbazepine (OXC)."}

{"project":"LitCoin-entities","denotations":[{"id":"3358","span":{"begin":0,"end":23},"obj":"ChemicalEntity"},{"id":"3359","span":{"begin":25,"end":34},"obj":"ChemicalEntity"},{"id":"3360","span":{"begin":36,"end":103},"obj":"ChemicalEntity"},{"id":"3361","span":{"begin":116,"end":134},"obj":"ChemicalEntity"},{"id":"3362","span":{"begin":275,"end":288},"obj":"ChemicalEntity"},{"id":"3363","span":{"begin":290,"end":293},"obj":"ChemicalEntity"},{"id":"3364","span":{"begin":299,"end":312},"obj":"ChemicalEntity"},{"id":"3365","span":{"begin":314,"end":317},"obj":"ChemicalEntity"}],"attributes":[{"id":"A6","pred":"db_id","subj":"3358","obj":"MESH:C416835"},{"id":"A7","pred":"db_id","subj":"3359","obj":"MESH:C416835"},{"id":"A8","pred":"db_id","subj":"3360","obj":"MESH:C416835"},{"id":"A9","pred":"db_id","subj":"3361","obj":"MESH:D000927"},{"id":"A10","pred":"db_id","subj":"3362","obj":"MESH:D002220"},{"id":"A11","pred":"db_id","subj":"3363","obj":"MESH:D002220"},{"id":"A12","pred":"db_id","subj":"3364","obj":"MESH:C036006"},{"id":"A13","pred":"db_id","subj":"3365","obj":"MESH:C036006"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine (CBZ) and oxcarbazepine (OXC)."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T5","span":{"begin":16,"end":23},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":25,"end":30},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":110,"end":115},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":149,"end":152},"obj":"GeneOrGeneProduct"}],"text":"Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine (CBZ) and oxcarbazepine (OXC)."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T3","span":{"begin":25,"end":30},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":110,"end":115},"obj":"GeneOrGeneProduct"}],"text":"Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine (CBZ) and oxcarbazepine (OXC)."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T6","span":{"begin":0,"end":23},"obj":"ChemicalEntity"},{"id":"T8","span":{"begin":25,"end":34},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":45,"end":52},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":67,"end":89},"obj":"ChemicalEntity"},{"id":"T11","span":{"begin":92,"end":103},"obj":"ChemicalEntity"},{"id":"T13","span":{"begin":116,"end":134},"obj":"ChemicalEntity"},{"id":"T14","span":{"begin":275,"end":288},"obj":"ChemicalEntity"},{"id":"T16","span":{"begin":290,"end":293},"obj":"ChemicalEntity"},{"id":"T17","span":{"begin":299,"end":312},"obj":"ChemicalEntity"},{"id":"T19","span":{"begin":314,"end":317},"obj":"ChemicalEntity"}],"attributes":[{"id":"A6","pred":"ID:","subj":"T6","obj":"C416835"},{"id":"A7","pred":"ID:","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_87016"},{"id":"A8","pred":"ID:","subj":"T8","obj":"C416835"},{"id":"A9","pred":"ID:","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_48076"},{"id":"A10","pred":"ID:","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_47802"},{"id":"A11","pred":"ID:","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_37622"},{"id":"A12","pred":"ID:","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_23004"},{"id":"A13","pred":"ID:","subj":"T13","obj":"ChemicalEntity"},{"id":"A14","pred":"ID:","subj":"T14","obj":"D002220"},{"id":"A15","pred":"ID:","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_3387"},{"id":"A16","pred":"ID:","subj":"T16","obj":"D002220"},{"id":"A17","pred":"ID:","subj":"T17","obj":"D000078330"},{"id":"A18","pred":"ID:","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_7824"},{"id":"A19","pred":"ID:","subj":"T19","obj":"D000078330"}],"text":"Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine (CBZ) and oxcarbazepine (OXC)."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T3","span":{"begin":25,"end":28},"obj":"OrganismTaxon"}],"text":"Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine (CBZ) and oxcarbazepine (OXC)."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T19","span":{"begin":314,"end":317},"obj":"ChemicalEntity"},{"id":"T17","span":{"begin":299,"end":312},"obj":"ChemicalEntity"},{"id":"T16","span":{"begin":290,"end":293},"obj":"ChemicalEntity"},{"id":"T14","span":{"begin":275,"end":288},"obj":"ChemicalEntity"},{"id":"T13","span":{"begin":116,"end":134},"obj":"ChemicalEntity"},{"id":"T11","span":{"begin":92,"end":103},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":67,"end":89},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":45,"end":52},"obj":"ChemicalEntity"},{"id":"T8","span":{"begin":25,"end":34},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":0,"end":23},"obj":"ChemicalEntity"},{"id":"T36705","span":{"begin":25,"end":28},"obj":"OrganismTaxon"}],"attributes":[{"id":"A19","pred":"ID:","subj":"T19","obj":"D000078330"},{"id":"A18","pred":"ID:","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_7824"},{"id":"A17","pred":"ID:","subj":"T17","obj":"D000078330"},{"id":"A16","pred":"ID:","subj":"T16","obj":"D002220"},{"id":"A14","pred":"ID:","subj":"T14","obj":"D002220"},{"id":"A15","pred":"ID:","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_3387"},{"id":"A13","pred":"ID:","subj":"T13","obj":"ChemicalEntity"},{"id":"A12","pred":"ID:","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_23004"},{"id":"A11","pred":"ID:","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_37622"},{"id":"A10","pred":"ID:","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_47802"},{"id":"A9","pred":"ID:","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_48076"},{"id":"A8","pred":"ID:","subj":"T8","obj":"C416835"},{"id":"A7","pred":"ID:","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_87016"},{"id":"A6","pred":"ID:","subj":"T6","obj":"C416835"}],"text":"Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine (CBZ) and oxcarbazepine (OXC)."}